ArticleCritical care (London, England)2010
Resuscitation with low volume hydroxyethylstarch 130 kDa/0.4 is not associated with acute kidney injury.
Article in Critical care (London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 41 citations in OpenAlex.
- Early fluid resuscitation with hydroxyethyl starch 130/0.4 (6%) in severe burn injury: a randomized, controlled, double-blind clinical trial.Critical care (London, England) · 2013Trial
- Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study.Critical care (London, England) · 2012Trial
- The effect of HES130/0.4 sodium chloride solution on kidney function following early fluid resuscitation in shock patients.Translational andrology and urology · 2021Article
- Polymer therapeutics in surgery: the next frontier.Journal of interdisciplinary nanomedicine · 2016Review
- Hydroxyethyl starch and acute kidney injury in orthotopic liver transplantation: a single-center retrospective review.Anesthesia and analgesia · 2015Article
- Reporting bias in trials of volume resuscitation with hydroxyethyl starch.Wiener klinische Wochenschrift · 2014Review
- Kidney function after the intraoperative use of 6% tetrastarches (HES 130/0.4 and 0.42).Journal of anesthesia · 2014Review
- Pros and cons of tetrastarch solution for critically ill patients.Journal of intensive care · 2014Review
- Concerns about renal safety of HES 130.Critical care (London, England) · 2013Article
- Sepsis: a review for the neurohospitalist.The Neurohospitalist · 2012Article
- Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients.Intensive care medicine · 2012Article
- Fluid management and risk factors for renal dysfunction in patients with severe sepsis and/or septic shock.Critical care (London, England) · 2012Article
- The role of renal hypoperfusion in development of renal microcirculatory dysfunction in endotoxemic rats.Intensive care medicine · 2011Article
- To dose or not to dose: that is the (starch) question ...Critical care (London, England) · 2010Article
- Formulation and development of plasma volume expander using natural and modified starch fromInternational journal of pharmaceutical investigationArticle
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcute kidney injury (AKI) in the ICU is associated with poorer prognosis. Hydroxyethylstarch (HES) solutions are fluid resuscitation colloids frequently used in the ICU with controversial nephrotoxic adverse effects. Our study objective was to evaluate HES impact on renal function and organ failures.
methodsThis observational retrospective study included 363 patients hospitalized for more than 72 hours in our ICU. A hundred and sixty eight patients received HES during their stay and 195 did not. We recorded patients' baseline characteristics on admission and type and volume of fluid resuscitation during the first 3 weeks of ICU stay. We also noted the evolution of urine output, the risk of renal dysfunction, injury to the kidney, failure of kidney function, loss of kidney function and end-stage kidney disease (RIFLE) classification and sepsis related organ failure assessment (SOFA) score over 3 weeks.
resultsPatients in the HES group were more severely ill on admission but AKI incidence was similar, as well as ICU mortality. The evolution of urine output (P = 0.74), RIFLE classification (P = 0.44) and SOFA score (P = 0.23) was not different. However, HES volumes administered were low (763+/-593 ml during the first 48 hours).
conclusionsVolume expansion with low volume HES 130 kDa/0.4 was not associated with AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.